Focus: Elicio Therapeutics is a Boston-based biotech company focused on developing HPV-induced cancer treatments, primarily targeting oncology indications through immunotherapy approaches.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Best suited for researchers and scientists seeking early-stage oncology exposure with high risk tolerance; limited for those prioritizing job security or rapid advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Elicio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Elicio Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo